AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item: http://hdl.handle.net/11055/569
Title: New Therapy for Refractory Chronic Mechanical Low Back Pain-Restorative Neurostimulation to Activate the Lumbar Multifidus: One Year Results of a Prospective Multicenter Clinical Trial
Authors: Deckers, Kristiaan
De Smedt, Kris
Mitchell,Bruce
Vivian, David
Russo, Marc
Georgius, Peter
Green, Matthew
Vieceli, John
Eldabe, Sam
Gulve, Ashish
Van Buyten, Jean-Pierre
Smet, Iris
Mehta, Vivek
Ramaswamy, Shankar
Baranidharan, Ganesan
Sullivan, Richard
Gassin, Robert
Rathmell, James
Gilligan, Chris
ANZCA/FPM Author: Sullivan, R
Georgius, Peter
Russo, M
Keywords: Arthrogenic muscle inhibition
chronic nonspecific low back pain
electrical stimulation
lumbar multifidus
motor control
Issue Date: Jan-2018
Citation: 21(1):48-55
Abstract: OBJECTIVES: The purpose of the international multicenter prospective single arm clinical trial was to evaluate restorative neurostimulation eliciting episodic contraction of the lumbar multifidus for treatment of chronic mechanical low back pain (CMLBP) in patients who have failed conventional therapy and are not candidates for surgery or spinal cord stimulation (SCS). MATERIALS AND METHODS: Fifty-three subjects were implanted with a neurostimulator (ReActiv8, Mainstay Medical Limited, Dublin, Ireland). Leads were positioned bilaterally with electrodes close to the medial branch of the L2 dorsal ramus nerve. The primary outcome measure was low back pain evaluated on a 10-Point Numerical Rating Scale (NRS). Responders were defined as subjects with an improvement of at least the Minimal Clinically Important Difference (MCID) of ≥2-point in low back pain NRS without a clinically meaningful increase in LBP medications at 90 days. Secondary outcome measures included Oswestry Disability Index (ODI) and Quality of Life (QoL; EQ-5D). RESULTS: For 53 subjects with an average duration of CLBP of 14 years and average NRS of 7 and for whom no other therapies had provided satisfactory pain relief, the responder rate was 58%. The percentage of subjects at 90 days, six months, and one year with ≥MCID improvement in single day NRS was 63%, 61%, and 57%, respectively. Percentage of subjects with ≥MCID improvement in ODI was 52%, 57%, and 60% while those with ≥MCID improvement in EQ-5D was 88%, 82%, and 81%. There were no unanticipated adverse events (AEs) or serious AEs related to the device, procedure, or therapy. The initial surgical approach led to a risk of lead fracture, which was mitigated by a modification to the surgical approach. CONCLUSIONS: Electrical stimulation to elicit episodic lumbar multifidus contraction is a new treatment option for CMLBP. Results demonstrate clinically important, statistically significant, and lasting improvement in pain, disability, and QoL.
URI: http://hdl.handle.net/11055/569
DOI: 10.1111/ner.12741
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29244235
ISSN: 1094-7159
Study Name: NCT01985230: ReActiv8-A
Journal Title: Neuromodulation
Type: Journal Article
Affiliates: GZA Hospitals, Wilrijk, Belgium
Monash Clinical Research Pty Ltd, Clayton, VIC, Australia
Hunter Pain Clinic, Broadmeadow, NSW, Australia
Sunshine Coast Clinical Research, Noosa Heads, QLD, Australia
Pain Medicine of South Australia, Welland, SA, Australia
The James Cook University Hospital, Middlesbrough, UK
Algemeen Ziekenhuis Nikolaas, Sint-Niklaas, Belgium
St. Bartholomew's Hospital, London, UK
Leeds Teaching Hospitals NHS Trust, Leeds, UK
Precision Neurosurgery, Kew, VIC, Australia
Brigham and Women's Healthcare, Harvard Medical School, Boston, MA, USA
Study/Trial: Prospective Cohort Study
Appears in Collections:Scholarly and Clinical

Files in This Item:
File Description SizeFormat 
New Therapy for Refractory Chronic Mechanical Low Back Pain (ID 59335).pdf
  Restricted Access
350.75 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.